In what clinical scenarios, if any, would you consider using sacituzumab govitecan prior to trastuzumab deruxtecan for HR+/HER2- metastatic breast cancer treatment?  

ASCENT-07 data recently did not meet endpoint for progression-free survival for sacituzumab govitecan as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer compared to other chemotherapies.